世界卫生组织胰胆细胞病理学报告系统。

Martha B Pitman
{"title":"世界卫生组织胰胆细胞病理学报告系统。","authors":"Martha B Pitman","doi":"10.5858/arpa.2023-0411-RA","DOIUrl":null,"url":null,"abstract":"<p><strong>Context.—: </strong>The World Health Organization (WHO) Reporting System for Pancreaticobiliary Cytopathology (WHO System) is the product of a joint venture between the World Health Organization, the International Academy of Cytology, and the International Agency for Research on Cancer. The WHO System revises the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology (PSC System) and replaces the 6-tiered system with a 7-tiered system.</p><p><strong>Objective.—: </strong>To explain the WHO System and the differences with the PSC System.</p><p><strong>Data sources.—: </strong>The WHO System and the PSC System of Reporting Pancreaticobiliary Cytopathology.</p><p><strong>Conclusions.—: </strong>The diagnostic categories of the WHO System are \"Insufficient/Inadequate/Nondiagnostic\"; \"Benign (Negative for Malignancy)\"; \"Atypical\"; \"Pancreaticobiliary Neoplasm, Low Risk/Low Grade (PaN-Low)\"; \"Pancreatic Neoplasm, High Risk/High Grade (PaN-High)\"; \"Suspicious for Malignancy\"; and \"Malignant.\" In the WHO System, the \"benign\" category includes both nonneoplastic and neoplastic lesions, so the \"Neoplastic: Benign\" category of the PSC system has been eliminated. Low-grade malignancies, pancreatic neuroendocrine tumors (PanNETs), and solid-pseudopapillary neoplasm (SPN) classified as \"Neoplastic: Other\" in the PSC System are classified as \"Malignant\" in the WHO System, leaving in the \"Neoplasm\" category intraductal lesions, which are divided into 2 new diagnostic categories: \"Pancreaticobiliary Neoplasm (PaN)-Low Risk/Grade\" and \"PaN-High Risk/Grade.\" As with the PSC System, the WHO System advocates close correlation with imaging and encourages incorporation of ancillary testing into the final diagnosis, such as biochemical (carcinoembryonic antigen [CEA] and amylase) and molecular testing. The WHO System includes risk of malignancy per category, and reporting and diagnostic management options that recognize the variations in resources of low- and middle-income countries.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"e39-e46"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The World Health Organization Reporting System for Pancreaticobiliary Cytopathology: Review and Comparison to the Papanicolaou Society of Cytopathology System.\",\"authors\":\"Martha B Pitman\",\"doi\":\"10.5858/arpa.2023-0411-RA\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Context.—: </strong>The World Health Organization (WHO) Reporting System for Pancreaticobiliary Cytopathology (WHO System) is the product of a joint venture between the World Health Organization, the International Academy of Cytology, and the International Agency for Research on Cancer. The WHO System revises the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology (PSC System) and replaces the 6-tiered system with a 7-tiered system.</p><p><strong>Objective.—: </strong>To explain the WHO System and the differences with the PSC System.</p><p><strong>Data sources.—: </strong>The WHO System and the PSC System of Reporting Pancreaticobiliary Cytopathology.</p><p><strong>Conclusions.—: </strong>The diagnostic categories of the WHO System are \\\"Insufficient/Inadequate/Nondiagnostic\\\"; \\\"Benign (Negative for Malignancy)\\\"; \\\"Atypical\\\"; \\\"Pancreaticobiliary Neoplasm, Low Risk/Low Grade (PaN-Low)\\\"; \\\"Pancreatic Neoplasm, High Risk/High Grade (PaN-High)\\\"; \\\"Suspicious for Malignancy\\\"; and \\\"Malignant.\\\" In the WHO System, the \\\"benign\\\" category includes both nonneoplastic and neoplastic lesions, so the \\\"Neoplastic: Benign\\\" category of the PSC system has been eliminated. Low-grade malignancies, pancreatic neuroendocrine tumors (PanNETs), and solid-pseudopapillary neoplasm (SPN) classified as \\\"Neoplastic: Other\\\" in the PSC System are classified as \\\"Malignant\\\" in the WHO System, leaving in the \\\"Neoplasm\\\" category intraductal lesions, which are divided into 2 new diagnostic categories: \\\"Pancreaticobiliary Neoplasm (PaN)-Low Risk/Grade\\\" and \\\"PaN-High Risk/Grade.\\\" As with the PSC System, the WHO System advocates close correlation with imaging and encourages incorporation of ancillary testing into the final diagnosis, such as biochemical (carcinoembryonic antigen [CEA] and amylase) and molecular testing. The WHO System includes risk of malignancy per category, and reporting and diagnostic management options that recognize the variations in resources of low- and middle-income countries.</p>\",\"PeriodicalId\":93883,\"journal\":{\"name\":\"Archives of pathology & laboratory medicine\",\"volume\":\" \",\"pages\":\"e39-e46\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of pathology & laboratory medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5858/arpa.2023-0411-RA\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of pathology & laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5858/arpa.2023-0411-RA","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景世界卫生组织(WHO)胰胆管细胞病理学报告系统(WHO系统)是世界卫生组织、国际细胞学学会和国际癌症研究机构联合推出的产物。世卫组织体系修订了巴氏细胞病理学会胰胆管细胞学报告体系(PSC 体系),并用 7 级体系取代了 6 级体系:解释 WHO 系统以及与 PSC 系统的区别:WHO系统和PSC胰胆管细胞病理学报告系统:WHO系统的诊断类别为 "不充分/不适当/无法诊断"、"良性(恶性肿瘤阴性)"、"非典型"、"胰胆管肿瘤,低风险/低级别(PaN-Low)"、"胰腺肿瘤,高风险/高级别(PaN-High)"、"恶性肿瘤可疑 "和 "恶性"。在世界卫生组织系统中,"良性 "类别包括非肿瘤性和肿瘤性病变,因此 PSC 系统中的 "肿瘤性:良性 "类别已被取消。低度恶性肿瘤、胰腺神经内分泌肿瘤(PanNET)和实性假乳头状瘤(SPN)在 PSC 系统中归类为 "肿瘤性:其他":在 PSC 系统中归类为 "肿瘤:其他 "的实体假乳头状瘤(SPN)在世卫组织系统中归类为 "恶性",剩下的 "肿瘤 "类别中的导管内病变被分为两个新的诊断类别:"胰胆管肿瘤(PaN)-低危/分级 "和 "PaN-高危/分级"。与 PSC 系统一样,WHO 系统主张与影像学密切相关,并鼓励将辅助检测纳入最终诊断,如生化检测(癌胚抗原 [CEA] 和淀粉酶)和分子检测。世卫组织系统包括每个类别的恶性肿瘤风险,以及报告和诊断管理选项,承认中低收入国家资源的差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The World Health Organization Reporting System for Pancreaticobiliary Cytopathology: Review and Comparison to the Papanicolaou Society of Cytopathology System.

Context.—: The World Health Organization (WHO) Reporting System for Pancreaticobiliary Cytopathology (WHO System) is the product of a joint venture between the World Health Organization, the International Academy of Cytology, and the International Agency for Research on Cancer. The WHO System revises the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology (PSC System) and replaces the 6-tiered system with a 7-tiered system.

Objective.—: To explain the WHO System and the differences with the PSC System.

Data sources.—: The WHO System and the PSC System of Reporting Pancreaticobiliary Cytopathology.

Conclusions.—: The diagnostic categories of the WHO System are "Insufficient/Inadequate/Nondiagnostic"; "Benign (Negative for Malignancy)"; "Atypical"; "Pancreaticobiliary Neoplasm, Low Risk/Low Grade (PaN-Low)"; "Pancreatic Neoplasm, High Risk/High Grade (PaN-High)"; "Suspicious for Malignancy"; and "Malignant." In the WHO System, the "benign" category includes both nonneoplastic and neoplastic lesions, so the "Neoplastic: Benign" category of the PSC system has been eliminated. Low-grade malignancies, pancreatic neuroendocrine tumors (PanNETs), and solid-pseudopapillary neoplasm (SPN) classified as "Neoplastic: Other" in the PSC System are classified as "Malignant" in the WHO System, leaving in the "Neoplasm" category intraductal lesions, which are divided into 2 new diagnostic categories: "Pancreaticobiliary Neoplasm (PaN)-Low Risk/Grade" and "PaN-High Risk/Grade." As with the PSC System, the WHO System advocates close correlation with imaging and encourages incorporation of ancillary testing into the final diagnosis, such as biochemical (carcinoembryonic antigen [CEA] and amylase) and molecular testing. The WHO System includes risk of malignancy per category, and reporting and diagnostic management options that recognize the variations in resources of low- and middle-income countries.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信